Investing in trust with leading edge technology
Dade Behring | Medical diagnostics

Dade Behring was developing a new immunoassay platform that would revolutionise the future of clinical diagnostics.

At the leading edge of technology, the automated system would not be available for commercial release for two to three years.

This created a major challenge in an industry with a seven year buying cycle.

Pathology laboratories and hospitals would have to hold off investing for a yet-to-be-proven system or buy from a competitor. Dade Behring’s local success was such that the first of the new systems in the world was sold into Australian labs.

Investing in trust with leading edge technologyDade Behring | Medical diagnostics

 

Dade Behring was developing a new immunoassay platform that would revolutionise the future of clinical diagnostics.

At the leading edge of technology, the automated system would not be available for commercial release for two to three years.

This created a major challenge in an industry with a seven year buying cycle.

Pathology laboratories and hospitals would have to hold off investing for a yet-to-be-proven system or buy from a competitor. Dade Behring’s local success was such that the first of the new systems in the world was sold into Australian labs.

Dade Behring | Medical diagnostics

 

Dade Behring | Medical diagnostics

 

Dade Behring | Medical diagnostics

 

Dade Behring | Medical diagnostics